Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is a significant cause of morbidity and mortality, distinct from healthcare-associated MRSA (HA-MRSA). CA-MRSA infections occur in otherwise healthy individuals without predisposing risk factors and are more virulent and transmissible than HA-MRSA. CA-MRSA strains, such as USA300, have spread globally and are now a major cause of community infections, particularly in the US. These strains are often non-multidrug resistant and carry genetic elements like SCCmecIV, which facilitate their transmission. CA-MRSA is associated with severe infections, including necrotizing pneumonia and osteomyelitis, and is more easily transmitted than HA-MRSA. Diagnosis involves isolating S. aureus from clinical samples, with susceptibility tests distinguishing CA-MRSA from HA-MRSA. Treatment options include oral agents like clindamycin, tetracyclines, and TMP-SMX, while parenteral therapies like vancomycin remain first-line for severe infections. Newer agents, such as linezolid and beta-lactams, show promise. Prevention strategies include reducing transmission through hygiene and developing vaccines. Despite advances, CA-MRSA remains a significant public health challenge due to its virulence and resistance to antibiotics. Understanding its genetic and molecular characteristics is crucial for developing effective therapies and prevention strategies.Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is a significant cause of morbidity and mortality, distinct from healthcare-associated MRSA (HA-MRSA). CA-MRSA infections occur in otherwise healthy individuals without predisposing risk factors and are more virulent and transmissible than HA-MRSA. CA-MRSA strains, such as USA300, have spread globally and are now a major cause of community infections, particularly in the US. These strains are often non-multidrug resistant and carry genetic elements like SCCmecIV, which facilitate their transmission. CA-MRSA is associated with severe infections, including necrotizing pneumonia and osteomyelitis, and is more easily transmitted than HA-MRSA. Diagnosis involves isolating S. aureus from clinical samples, with susceptibility tests distinguishing CA-MRSA from HA-MRSA. Treatment options include oral agents like clindamycin, tetracyclines, and TMP-SMX, while parenteral therapies like vancomycin remain first-line for severe infections. Newer agents, such as linezolid and beta-lactams, show promise. Prevention strategies include reducing transmission through hygiene and developing vaccines. Despite advances, CA-MRSA remains a significant public health challenge due to its virulence and resistance to antibiotics. Understanding its genetic and molecular characteristics is crucial for developing effective therapies and prevention strategies.